Mothercare
plc
Interim results
announcement
Mothercare plc ("Mothercare" "the
Company" or "the Group"), the highly trusted British heritage
international brand and franchise operator, that connects with the
parents of newborn babies and children across multiple product
categories, today announces unaudited half year results for the
26-week period to 28 September 2024 ("H1 FY25"). The comparative
period was a 26-week period to 23 September 2023 ("H1
FY24").
Key Highlights
·
Worldwide retail sales by
franchise partners of £121.2 million (2023: £137.2 million), a
decrease of 12% on last year (9% down at constant currency), with
the decline largely resulting from the unchanged conditions in our
Middle Eastern markets.
·
Adjusted EBITDA of £1.7 million (H1 FY24: £3.6
million) decreased by 53%.
·
Group adjusted profit from operations decreased
by 68% to £1.1 million (H1 FY24: £3.4 million).
·
Group adjusted loss before taxation of £1.4 million (H1
FY24: £1.8 million profit).
·
Net debt increased to £17.1 million (£15.8
million at 23 September 2023).
· Following the
Joint venture deal and refinancing announced on 17 October 2024,
the term loan of £19.9 million included in the above net debt
figure, was reduced to £8.0 million.
Our Group
|
|
|
|
|
|
26 weeks
to
|
26 weeks
to
|
26 weeks
to
|
26 weeks
to
|
|
28 Sep
2024
|
23 Sep
2023
|
24 Sep
2022
|
25 Sep
2021
|
|
|
|
|
|
Turnover £m
|
21.0
|
29.0
|
38.5
|
41.7
|
Adjusted
EBITDA2
£m
|
1.7
|
3.6
|
3.2
|
5.6
|
Adjusted profit from
operations 2
£m
|
1.1
|
3.4
|
2.9
|
5.2
|
Adjusted (loss)/profit before
taxation2
£m
|
(1.4)
|
1.8
|
1.7
|
3.6
|
(Loss)/profit for the period
£m
|
(1.8)
|
1.7
|
0.4
|
3.6
|
Adjusted basic (loss)/earnings per
share2
|
(0.3)p
|
0.2p
|
0.2p
|
0.9p
|
Basic (loss)/ earnings per
share
|
(0.3)p
|
0.3p
|
0.1p
|
1.0p
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Our Franchise
partners
|
|
|
|
|
|
26 weeks
to
|
26 weeks
to
|
26 weeks
to
|
26 weeks
to
|
|
28 Sep
2024
|
23 Sep
2023
|
24 Sep
2022
|
25 Sep
2021
|
|
|
|
|
|
Worldwide retail
sales1 £m
|
121.2
|
137.2
|
162.1
|
184.3
|
Online retail sales £m
|
12.2
|
13.7
|
13.1
|
17.6
|
|
|
|
|
|
Total number of stores
|
440
|
500
|
562
|
740
|
Space (k) sq. ft.
|
1,100
|
1,201
|
1,345
|
1,967
|
Clive Whiley, Chairman of
Mothercare plc, commented:
"Since the half-year end we announced both a
new £30 million joint venture for the South Asian region, with
Reliance Brands Holding UK Limited ("Reliance") and subsequent
revised financing arrangements, reducing secured debt facilities by
60% to £8 million and our annualised cash interest cost by over
75%.
We have immediately utilised this new India
joint venture and refinancing as a springboard for a de-leveraged
Mothercare to explore the full bandwidth of growth opportunities
through connections with other businesses, the development of our
branded product ranges and licensing within and beyond our existing
perimeters.
Our results continue to reflect the impact of
the continuing uncertainty on our franchise partners' operations in
the Middle East. We are now focused upon restoring critical mass
alongside delivering our remaining core objectives. This is an
exciting prospect for all our partners, colleagues and stakeholders
as we can finally leave behind the turmoil of recent years that
Mothercare has successfully come through."
Investor and analyst enquiries
to:
Mothercare plc
Email: investorrelations@mothercare.com
Clive Whiley, Chairman
Andrew Cook, Chief Financial
Officer
Deutsche Numis
Tel: 020 7260 1000
(NOMAD & Joint Corporate
Broker)
Luke Bordewich
Cavendish Capital Markets Limited
Tel: 020
7220 0500
(Joint Corporate
Broker)
Carl Holmes
Media enquiries to:
MHP
Email: mothercare@mhpc.com
Rachel Farrington
Tel: 07801 894577
Tim Rowntree
Notes
1 - Worldwide retail sales are total international retail
franchise partner sales to end customers (which are estimated and
unaudited).
2 - Adjusted
profit after taxation is stated before the impact of the adjusting
items set out in note 4.
3 - Net debt is defined as total
borrowings, cash at bank and IFRS 16 lease liabilities.
4 - This announcement contains
certain forward-looking statements concerning the Group. Although
the Board believes its expectations are based on reasonable
assumptions, the matters to which such statements refer may be
influenced by factors that could cause actual outcomes and results
to be materially different. The forward-looking statements speak
only as at the date of this document and the Group does not
undertake any obligation to announce any revisions to such
statements, except as required by law or by any appropriate
regulatory authority.
5 - The information contained
within this announcement is deemed by the Company to constitute
inside information for the purposes of the Market Abuse Regulation
(EU) No 596/2014. Upon the publication of this announcement via a
Regulatory Information Service, this inside information is now
considered to be in the public domain.
6 - The
person responsible for the release of this announcement is Lynne
Medini, Group Company Secretary at Mothercare plc, Westside 1, London Road, Hemel Hempstead, HP3
9TD.
7 - Mothercare plc's Legal Entity Identifier ("LEI") number is
213800ZL6RPV9Z9GFO74.
Chairman's statement
Core Objectives
As detailed in our Full Year 2024
results statement, our principal focus since my appointment has
been to protect the underlying Mothercare brand intellectual
property value for the benefit of all stakeholders.
The new joint venture for the
South Asian region and coterminous refinancing, detailed below,
will further reduce the combined business and pension schemes
financing requirement and introduces significantly reduced cash
financing charges.
In addition, this establishes a
platform for step-change growth as we strive to sponsor growth in
our franchise partners' retail sales and store footprint alongside
exploring new territories and additional routes to
market.
Trading Update
As also noted in the Full Year
2024 results statement, our worldwide retail sales by franchise
partners of £121.2 million (2024: £137.2 million) were again
impacted by a combination of the continuing uncertainty in the
Middle East and the ongoing need for franchise partners to clear
old inventory. Online retail sales for the period remained at 10%
of total retail sales (H1 FY24: 10%). The year-on-year decline in
retail sales of 12% reduces to 9% at constant currency exchange
rates.
Performance in our Middle Eastern
region, especially in our largest single market, remains
challenging where the shape of our partner's retail offering in the
country continues to adapt to address evolving consumer behaviour,
pursuant to ongoing fiscal and legislative changes.
Adjusted EBITDA for the period
decreased to £1.7 million (2024: £3.6 million) leading to an
adjusted loss before taxation of £1.4 million (2024: £1.8 million
adjusted profit before taxation) principally due to high net
financing costs in the period, which have since been significantly
reduced for future periods.
Joint Venture and Refinancing
On 17 October we announced a
joint venture with an entry valuation of c£30 million for the South
Asian region with Reliance Brands Ltd ("Reliance"), a wholly owned
subsidiary of Reliance Industries Ltd, a Fortune 500 company and
the largest private sector corporation in India.
The Company received gross
consideration of £16 million on completion of these new
arrangements and secured reduced debt facilities of £8 million with
GB Europe Management Services Ltd ("Gordon Brothers"), in one
step:
• demonstrating the
inherent value of the Mothercare brand,
• creating an invigorated
partnership in the South Asian region with Reliance, one of the
world's largest, leading and respected business groups which will
bring symbiotic and synergistic benefits; and
• de-leveraging the business
to finally move forward and invest appropriately in the Company's
future development.
New South Asian Joint Venture Arrangements
Mothercare and Reliance created a
new joint venture covering Mothercare's franchise operations in
India, Nepal, Sri Lanka, Bhutan and Bangladesh, replacing the
previous franchise arrangement with Reliance covering India
alone.
Under the terms of these
arrangements, Reliance paid £16 million to acquire a 51% interest
in a new joint venture company, JVCO 2024 Ltd ("JVCo"). We retain a
residual 49% shareholding in JVCo and granted JVCo perpetual rights
for the use of the Mothercare brand and related intellectual
property in India, Nepal, Sri Lanka, Bhutan and
Bangladesh.
For the financial year ended 30
March 2024, our retail sales in India under the previous franchise
arrangements amounted to approximately £24 million and contributed
approximately £0.9 million to adjusted EBITDA. Whilst we will
receive revenues at lower rates than previously, we expect the
reinvigorated business to grow strongly and surpass previous
revenue levels over the next few years. We also expect to
benefit from both sourcing fees (supplying the joint venture with
product) together with the value creation accruing to our residual
49% equity stake in JVCo.
New Financing Arrangements with Gordon
Brothers
We applied part of the proceeds
received from Reliance towards a refinancing of the Company's
existing debt facilities with Gordon Brothers, replacing the
previous £19.5m term loan (which attracted interest at a rate of
13% per annum, plus SONIA, plus PIK interest of 1% per annum)
with:
• an £8m two
year term loan facility, attracting interest at a rate of 4.8% per
annum, plus SONIA (with a floor of 5.2%), plus PIK interest of 1%
per annum, rising to 2% per annum through the term of the loan;
and
• granted
Gordon Brothers warrants to subscribe up to 43.4m new ordinary
shares at a subscription price of 8.5p per share (the "Warrants"),
exercisable for five years from the date of issue, representing
approximately 7% of the Company's issued share capital (following
exercise in full of the Warrants).
Financial impact
We estimate that the restructuring
of our operations in South Asia and the associated sale of this 51%
stake in JVCo, will result in a taxable gain arising of
approximately £29 million and - after the use of certain
preexisting tax losses - a cash tax cost of approximately £3
million.
Pension Schemes
We continue to operate in
accordance with the revised recovery plan, agreed with the Trustees
last year, which includes total contributions (Deficit Repair
Contributions plus costs) in the financial years to March 2025 £2.0
million; March 2026 & 2027 £3.0 million; March 2028 & 2029
£4.0 million; March 2030 & 2031 £5.0 million and March 2032
£6.0 million and March 2033 £0.5 million aggregating to fully fund
the deficit by March 2033. We also continue to explore other
options to mitigate the pension scheme deficit.
Growth Opportunities
We intend to utilise the new South
Asian region joint venture and coterminous refinancing as a
catalyst to redouble our efforts to capitalise upon the
possibilities to grow the future global presence of the Mothercare
brand: through connections with other businesses, the development
of our branded product ranges and licensing within and beyond our existing perimeters .
Management & Board changes
On the creation of the new South
Asian joint venture and coterminous refinancing, Mark Newton Jones
indicated his intention to stand down from the Board at the AGM
held last month. I would like to thank Mark, both personally and on
behalf of the Board for his efforts since my appointment and we
wish him well with his future endeavours.
The day-to-day management of the
Group continues to be run by the Chief Financial Officer and the
Operating Board, with oversight from me as Chairman. We also
anticipate the search for a new Chief Executive Officer to be
fulfilled as a natural consequence of the multiple strategic
discussions currently in train.
Outlook
Our core objectives over recent
years were designed to protect and rebalance the Mothercare brand
IP value in a way that also promotes growth in our royalty income:
ultimately improving profitability and the covenant of the
underlying business, with benefits for both the actuarial
pension deficit and stock market rating purposes alike.
At a stroke the new South Asian
joint venture underlines the inherent strength of the business's
brand, coterminously supporting a material de-leveraging of the
balance sheet and allows us to wholly focus upon restoring critical
mass.
Indeed, we approach 2025 and
beyond with a renewed and growing sense of confidence given the
multiple opportunities ahead, notwithstanding our ongoing cautious
shorter-term outlook, due to the continuing challenges facing our
Middle East operations.
None of this would have been
possible without the continuing support from our Mothercare
colleagues, manufacturing & franchise partners, pension scheme
trustees and financial stakeholders alike, to whom we remain
grateful.
Clive Whiley
Chairman
Condensed consolidated income statement
For the 26 weeks ended 28 September
2024
|
|
26 weeks ended 28 September
2024
(Unaudited)
|
|
26 weeks
ended 23 September 2023
(Unaudited)
|
53 weeks
ended
30 March 2024
(Audited)
|
|
Note
|
Before adjusted
items
£ million
|
Adjusted
items1
£ million
|
Total
£ million
|
|
Before
adjusted items
£
million
|
Adjusted
items 1
£
million
|
Total
£
million
|
Total
£
million
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
21.0
|
-
|
21.0
|
|
29.0
|
-
|
29.0
|
56.2
|
Cost of sales
|
|
(13.0)
|
-
|
(13.0)
|
|
(19.0)
|
-
|
(19.0)
|
(36.6)
|
Gross profit
|
|
8.0
|
-
|
8.0
|
|
10.0
|
-
|
10.0
|
19.6
|
Administrative expenses
|
|
(6.9)
|
(0.4)
|
(7.3)
|
|
(6.6)
|
0.2
|
(6.4)
|
(13.3)
|
Impairment losses on
receivables
|
|
-
|
-
|
-
|
|
-
|
-
|
-
|
0.4
|
Profit from operations
|
|
1.1
|
(0.4)
|
0.7
|
|
3.4
|
0.2
|
3.6
|
6.7
|
Net finance costs
|
5
|
(2.5)
|
-
|
(2.5)
|
|
(1.6)
|
-
|
(1.6)
|
(3.8)
|
(Loss)/profit before taxation
|
|
(1.4)
|
(0.4)
|
(1.8)
|
|
1.8
|
0.2
|
2.0
|
2.9
|
Taxation
|
6
|
(0.0)
|
-
|
(0.0)
|
|
(0.3)
|
-
|
(0.3)
|
0.4
|
|
|
|
|
|
|
|
|
|
|
(Loss)/profit for the period
|
|
(1.4)
|
(0.4)
|
(1.8)
|
|
1.5
|
0.2
|
1.7
|
3.3
|
(Loss)/profit for the period attributable to equity holders of
the parent
|
(1.4)
|
(0.4)
|
(1.8)
|
|
1.5
|
0.2
|
1.7
|
3.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
|
|
|
|
|
|
|
|
Basic
|
7
|
(0.3)p
|
|
(0.3)p
|
0.3p
|
|
0.3p
|
0.6p
|
Diluted
|
7
|
(0.3 p
|
|
(0.3)p
|
0.3p
|
|
0.
p
|
0.6p
|
|
|
|
|
|
|
|
|
|
| |
(1)
Includes adjusted costs ( restructuring and reorganisation
costs). Adjusted items are one-off or significant in nature and or
/value. Excluding these items from the profit metrics provides
readers with helpful additional information on the performance of
the business across the periods because it is consistent with how
business performance is reviewed by the Board and Operating
Board.
Condensed consolidated statement
of comprehensive income
For the 26 weeks ended 28 September
2024
|
|
26 weeks
ended
28 September
2024
(Unaudited)
|
26 weeks
ended
23 September
2023
(Unaudited)
|
53 weeks
ended
30 March
2024
(Audited)
|
|
|
£ million
|
£
million
|
£
million
|
|
|
|
|
|
(Loss)/profit for the period
|
|
(1.8)
|
1.7
|
3.3
|
|
|
|
|
|
Items that will not be reclassified subsequently to the income
statement:
Actuarial gain/(loss) on defined
benefit pension schemes
|
|
3.8
|
(16.3)
|
(33.8)
|
Deferred tax relating to items not
reclassified
|
|
(1.0)
|
3.1
|
2.0
|
|
|
2.8
|
(13.2)
|
(31.8)
|
Items that may be reclassified subsequently to the income
statement:
|
|
|
|
|
Exchange differences on translation
of foreign operations
|
|
-
|
(0.1)
|
-
|
|
|
|
|
|
Other comprehensive income/(expense) for the
period
|
|
2.8
|
(13.3)
|
(31.8)
|
|
|
|
|
|
Total comprehensive income/(expense) for the period wholly
attributable to equity holders of the parent
|
|
1.0
|
(11.6)
|
(28.5)
|
|
|
|
|
|
|
|
|
|
|
|
| |
Condensed consolidated balance sheet
As at 28 September 2024
|
|
28 September
2024
(Unaudited)
|
23
September 2023
(Unaudited)
|
30 March
2024
(Audited)
|
|
|
|
|
|
|
Note
|
£ million
|
£
million
|
£
million
|
Non-current assets
|
|
|
|
|
Intangible assets
|
8
|
8.4
|
6.8
|
7.9
|
Property, plant and equipment
|
8
|
0.2
|
0.2
|
0.2
|
Right-of-use assets
|
|
-
|
0.2
|
0.1
|
Deferred
tax assets
|
|
3.5
|
2.7
|
3.4
|
|
|
12.1
|
9.9
|
11.6
|
Current assets
|
|
|
|
|
Inventories
|
|
0.7
|
0.7
|
0.6
|
Trade and
other receivables
|
|
6.1
|
5.1
|
4.3
|
Derivative
financial instruments
|
11
|
0.5
|
0.5
|
0.7
|
Current
tax asset
|
|
-
|
0.5
|
0.2
|
Cash and
cash equivalents
|
|
2.8
|
4.2
|
5.0
|
|
|
10.1
|
11.0
|
10.8
|
|
|
|
|
|
Total assets
|
|
20.2
|
20.9
|
22.4
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
Trade and
other payables
|
|
(9.5)
|
(7.5)
|
(8.1)
|
Lease
liabilities
|
|
-
|
(0.4)
|
(0.2)
|
Provisions
|
|
(0.1)
|
(0.7)
|
(0.3)
|
Current
tax liabilities
|
|
(0.1)
|
-
|
-
|
Borrowings
|
9
|
(19.9)
|
-
|
(19.7)
|
|
|
(29.6)
|
(8.6)
|
(28.3)
|
Non-current liabilities
|
|
|
|
|
Borrowings
|
9
|
-
|
(19.6)
|
-
|
Lease
liabilities
|
|
-
|
-
|
-
|
Retirement
benefit obligations
|
10
|
(20.6)
|
(6.0)
|
(24.2)
|
Deferred
tax liabilities
|
|
(1.0)
|
-
|
-
|
|
|
(21.6)
|
(25.6)
|
(24.2)
|
|
|
|
|
|
Total liabilities
|
|
(51.2)
|
(34.2)
|
(52.5)
|
|
|
|
|
|
Net liabilities
|
|
(29.0)
|
(13.3)
|
(30.1)
|
|
|
|
|
|
Equity attributable to equity holders of the
parent
|
|
|
|
|
Share
capital
|
|
89.3
|
89.3
|
89.3
|
Share
premium account
|
|
108.8
|
108.8
|
108.8
|
Own
shares
|
|
(0.2)
|
(0.2)
|
(0.2)
|
Translation reserve
|
|
(3.7)
|
(3.8)
|
(3.7)
|
Retained
deficit
|
|
(223.2)
|
(207.4)
|
(224.3)
|
Total equity
|
|
(29.0)
|
(13.3)
|
(30.1)
|
|
|
|
|
| |
Condensed consolidated statement
of changes in equity
For the 26 weeks ended 28 September
2024 (unaudited)
|
Share
capital
|
Share premium
account
|
Own shares
|
Translation
reserve
|
Retained
deficit
|
Total
equity |
|
£ million
|
£ million
|
£ million
|
£ million
|
£ million
|
£
million |
Balance as at 30 March 2024
|
89.3
|
108.8
|
(0.2)
|
(3.7)
|
(224.3)
|
(30.1) |
|
Loss for the period
|
-
|
-
|
-
|
-
|
(1.8)
|
(1.8) |
|
Other comprehensive income for the
period
|
-
|
-
|
-
|
-
|
2.8
|
2.8 |
Total comprehensive income for the period
|
-
|
-
|
-
|
-
|
1.0
|
1.0 |
Adjustments to equity for
equity-settled share-based payments
|
-
|
-
|
-
|
-
|
0.1
|
0.1 |
|
Balance at 28 September 2024
|
89.3
|
108.8
|
(0.2)
|
(3.7)
|
(223.2)
|
(29.0) |
For the 26 weeks ended 23 September
2023 (unaudited)
|
Share
capital
|
Share
premium account
|
Own
shares
|
Translation reserve
|
Retained
deficit
|
Total
equity
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
Balance as at 25 March
2023
|
89.3
|
108.8
|
(0.2)
|
(3.7)
|
(196.0)
|
(1.8)
|
Profit for the period
|
-
|
-
|
-
|
-
|
1.7
|
1.7
|
Other comprehensive expense for the
period
|
-
|
-
|
-
|
(0.1)
|
(13.2)
|
(13.3)
|
Total comprehensive expense for the
period
|
-
|
-
|
-
|
(0.1)
|
(11.5)
|
(11.6)
|
Adjustments to equity for
equity-settled share-based payments
|
-
|
-
|
-
|
-
|
0.1
|
0.1
|
Balance at 23 September
2023
|
89.3
|
108.8
|
(0.2)
|
(3.8)
|
(207.4)
|
(13.3)
|
For the 53 weeks ended 30 March
2024 (audited)
|
Share
capital
|
Share
premium account
|
Own
shares
|
Translation reserve
|
Retained
deficit
|
Total
equity
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
£
million
|
Balance at 25 March 2023
|
89.3
|
108.8
|
(0.2)
|
(3.7)
|
(196.0)
|
(1.8)
|
Items that will not be reclassified
subsequently to the
income statement
|
-
|
-
|
-
|
-
|
(31.8)
|
(31.8)
|
Other comprehensive
expense
|
-
|
-
|
-
|
-
|
(31.8)
|
(31.8)
|
Profit for the period
|
-
|
-
|
-
|
-
|
3.3
|
3.3
|
Total comprehensive
expense
|
-
|
-
|
-
|
-
|
(28.5)
|
(28.5)
|
Adjustment to equity for
equity-settled share-based payments
|
-
|
-
|
-
|
-
|
0.2
|
0.2
|
Balance at 30 March 2024
|
89.3
|
108.8
|
(0.2)
|
(3.7)
|
(224.3)
|
(30.1)
|
Condensed consolidated cash flow statement
For the 26 weeks ended 28 September
2024
|
Note
|
26 weeks
ended
28 September
2024
(Unaudited)
|
26 weeks
ended
23
September 2023
(Unaudited)
|
53 weeks
ended
30 March
2024
(Audited)
|
|
|
£ million
|
£
million
|
£
million
|
Net
cash flow from operating activities
|
13
|
0.0
|
(0.3)
|
4.8
|
Cash flows from investing activities
|
|
|
|
|
Purchase of property, plant and equipment
|
|
-
|
(0.1)
|
(0.1)
|
Purchase of intangibles - software
|
(0.8)
|
(0.6)
|
(2.2)
|
Cash
used in investing activities
|
|
(0.8)
|
(0.7)
|
(2.3)
|
Cash flows from financing activities
|
|
|
|
|
Proceeds from post administration
distribution
|
|
0.2
|
-
|
-
|
Interest paid
|
|
(1.5)
|
(1.7)
|
(4.2)
|
Repayments of obligations under
leases
|
|
(0.2)
|
(0.2)
|
(0.3)
|
Net
cash outflow from financing activities
|
|
(1.5)
|
(1.9)
|
(4.5)
|
|
|
|
|
|
Net decrease in cash and cash equivalents
|
|
(2.3)
|
(2.9)
|
(2.0)
|
|
|
|
|
|
Cash and cash equivalents at
beginning of period
|
|
5.0
|
7.1
|
7.1
|
Effect of foreign exchange rate
changes
|
|
0.1
|
-
|
(0.1)
|
Cash
and cash equivalents at end of period
|
|
2.8
|
4.2
|
5.0
|
|
|
|
|
|
| |
Notes to the condensed consolidated financial
statements
1 General
information
The review of the Group's business
activities, together with factors likely to affect its future
development, performance and position are set out in the Financial
Highlights and Chairman's Statement.
The results for the 26 weeks ended
28 September 2024 are unaudited.
These unaudited condensed
consolidated interim financial statements for the current period
and prior financial periods do not constitute statutory accounts as
defined in section 434 of the Companies Act 2006. A copy of the
statutory accounts for the 2024 financial year has been filed with
the Registrar of Companies. The 2024 financial statements are
available on the Group's website (www.mothercareplc.com).
The auditor has reported on these: their report was
unqualified.
2 Accounting Policies and
Standards
Basis of
preparation
These unaudited condensed
consolidated interim financial statements have been prepared in
accordance with the Disclosure and Transparency Rules of the UK
Financial Conduct Authority, and with IAS 34 'Interim Financial
Reporting'. Unless otherwise stated, the accounting policies
applied, and the judgements, estimates and assumptions made in
applying these policies, are consistent with those described in the
Annual Report and Financial Statements 2024. The financial period
represents the 26 weeks ended 28 September 2024. The comparative
periods are the 26 weeks ended 23 September 2023 and the 53 weeks
ended 30 March 2024.
Going
concern
Since the balance sheet date the IP
rights for the Mothercare brand for India, Bhutan, Bangladesh, Sri
Lanka and Nepal were transferred to JVCO 2024 Ltd, which was a
wholly owned subsidiary of the Group, at a value of £33.3 million.
On 17 October, in return for a 51% equity interest in JVCO 2024,
together with some royalty concessions, the Group received a gross
consideration of £16.0 million, from Reliance, our current
franchise partner in India.
From these proceeds Mothercare
repaid £11.5 million of its existing loan facility, reducing the
principal liability to £8 million and at the same time revised the
terms of facility including reducing the interest charged from13%
per annum plus SONIA plus an additional 1% per annum
payment-in-kind coupon to 4.8% per annum plus SONIA (with SONIA at
a floor of 5.2%) plus a 1% per annum payment-in-kind coupon for the
first 12 months, rising to 1.5% per annum for the 13 to 18 months
and then 2% per annum thereafter percentage and revising the
financial covenants.
The consolidated financial
information has been prepared on a going concern basis. When
considering the going concern assumption, the Directors of the
Group have reviewed a number of factors, including the Group's
trading results, the recent reduction in debt and interest charges
and its continued access to sufficient borrowing facilities against
the Group's latest forecasts and projections,
comprising:
• A Base Case forecast;
and
• A Sensitised forecast, which
applies sensitivities against the Base Case for reasonably possible
adverse variations in performance, reflecting the ongoing
volatility in our key markets
Notes to the condensed consolidated financial
statements
2 Accounting Policies and
Standards (continued)
Going concern
(continued)
The Sensitised scenario assumes the
following additional key assumption:
• A significant reduction in global
retail sales, which may result from subdued, consumer confidence or
disposable income or through store closures or weaker trading in
our markets, throughout the remainder of FY25 and FY26.
The Board's confidence in the
Group's Base Case forecast, which indicates that the Group will
operate with sufficient cash balances and within the financial
covenants of the loan facility, following the recent reduction and
revision of this facility and the Group's proven cash management
capability, supports our preparation of the financial statements on
a going concern basis.
However, as described in the
Chairman's statement, worldwide retails continue to be
impacted by a combination of the continuing
uncertainty in the Middle East and the ongoing need for franchise
partners to clear old inventory. If trading
conditions were to deteriorate beyond the level of risk applied in
the sensitised forecast owing to ongoing geopolitical tensions,
other global downturn in trade or low consumer demand, the Group
may need to renegotiate with its lender in order to secure waivers
to potential covenant breaches or have access to additional funding
to continue its trading activities. Whilst the directors believe
that the post year end deal with Reliance, as described above, has
now put the Group in a stronger position, it is acknowledged that,
in view of the above, there remains a material uncertainty which
may cast significant doubt about the Group's ability to continue as
a going concern. The financial statements do not include any
adjustments that would result if the Group was unable to continue
as a going concern.
Adoption of new
IFRSs
A number of new or amended
standards became applicable for the current reporting period. The
Group did not have to change its accounting policies or make
retrospective adjustments as a result of adopting these
standards.
Standards issued but not yet
effective
In August 2023, the IASB amended
IAS 21 to help entities to determine whether a currency is
exchangeable into another currency, and which spot exchange rate to
use when it is not. These new requirements will apply for annual
reporting periods beginning on or after 1 January 2025. The Group
does not expect these amendments to have a material impact on its
operations or financial statements.
Foreign currency
adjustments
Foreign currency monetary assets
and liabilities are revalued to the closing balance sheet rate
under IAS21 "The Effects of Changes in Foreign Exchange
Rates".
Notes to the condensed consolidated financial
statements
2 Accounting Policies and
Standards (continued)
Taxation
The taxation charge for the
26 week period is
calculated by applying the best estimate of the average annual
effective tax rate expected for the full year to the profit/loss
for the period after adjusting for any significant one-off items,
and a tax credit is recognised only to the extent that the
resulting tax asset is more than likely not to reverse.
Retirement
benefits
Payments to defined contribution
retirement benefit schemes are charged as an expense as they fall
due.
For defined benefit schemes, the
cost of providing benefits is determined using the Projected Unit
Credit Method, with actuarial valuations being carried out at each
balance sheet date. Actuarial gains and losses are recognised in
full in the period in which they occur. They are recognised outside
of the income statement and presented in other comprehensive
income.
Past service cost is recognised
immediately to the extent that the benefits are already
vested.
The retirement benefit obligation
recognised in the balance sheet represents the present value of the
defined benefit obligation less the fair value of scheme assets.
Any asset resulting from this calculation is limited to past
service cost, plus the present value of available
refunds.
The Group has an unconditional
right to a refund of surplus under the rules.
In consultation with the
independent actuaries to the schemes, the valuation of the pension
obligation has been updated to reflect: current market discount
rates; current market values of investments and actual investment
returns; and also for any other events that would significantly
affect the pension liabilities. The impact of these changes in
assumptions and events has been estimated in arriving at the
valuation of the pension obligation.
Alternative performance
measures (APMs)
In the reporting of financial
information, the Directors have adopted various APMs of historical
or future financial performance, position or cash flows other than
those defined or specified under International Financial Reporting
Standards (IFRS).
These measures are not defined by
IFRS and therefore may not be directly comparable with other
companies' APMs, including those in the Group's
industry.
APMs should be considered in
addition to, and are not intended to be a substitute for, or
superior to, IFRS measures.
Purpose
The Directors believe that these
APMs assist in providing additional useful information on the
performance and position of the Group because they are consistent
with how business performance is reported to the Board and
Operating Board.
APMs are also used to enhance the
comparability of information between reporting periods and
geographical units (such as like-for-like sales), by adjusting for
non-recurring or uncontrollable factors which affect IFRS measures,
to aid the user in understanding the Group's
performance.
Consequently, APMs are used by the
Directors and management for performance analysis, planning,
reporting and incentive setting purposes and have remained
consistent with prior year.
Notes to the condensed consolidated financial
statements
2
Accounting Policies and Standards (continued)
The key APMs that the Group has
focused on during the period are as follows:
Group worldwide sales
Group worldwide sales are total
international retail sales from our franchise partners. Total Group
revenue is a statutory number and is made up of total receipts from
our franchise partners, which includes royalty payments, and the
cost of goods dispatched to international franchise
partners.
Profit/(loss) before adjusted items
The Group's policy is to exclude
items that are considered to be significant in both nature and/or
quantum and where treatment as an adjusted item provides
stakeholders with additional useful
information to assess the
year-on-year trading performance of the Group.
3 Segmental
information
IFRS 8 requires operating segments
to be identified on the basis of internal reports about components
of the Group that are regularly reported to the Group's executive
decision makers (comprising the executive directors and operating
board) in order to allocate resources to the segments and assess
their performance. Under IFRS 8, the Group has not identified that
its continuing operations represent more than one operating
segment.
The results of franchise partners
are not reported separately, nor are resources allocated on a
franchise partner by franchise partner basis, and therefore have
not been identified to constitute separate operating
segments.
Notes to the condensed consolidated financial
statements
4
Adjusted items
Due to their significance or
one-off nature, certain items have been classified as adjusted
items as follows:
|
26 weeks
ended
28 September
2024
(Unaudited)
|
26 weeks
ended
23
September 2023
(Unaudited)
|
53 weeks
ended
30 March
2024
(Audited)
|
£ million
|
£
million
|
£
million
|
Adjusted (costs)/income:
|
|
|
|
Restructuring (costs)/income
included in finance costs
|
-
|
-
|
(0.4)
|
Restructuring (costs)/income
included in administrative expenses
|
(0.4)
|
0.2
|
0.2
|
|
|
|
|
Adjusted items before tax
|
(0.4)
|
0.2
|
(0.2)
|
Restructuring (costs)/income included in administrative
expenses - (£0.4) million (H1 FY24: £0.2 million
income)
The current year costs relates
to:
• £0.2 million redundancy payments made to certain staff during
the period.
• £0.1 million costs relating to decommissioning of old IT
systems.
• £0.1 million costs arising from technical challenges relating
to the new IT system.
The prior year income relates to
£0.4 million credits arising in relation to the profit on disposal
of Mothercare UK Limited business which went into administration,
this was offset by £0.2m of severance payments made.
5 Net finance
costs
|
|
26 weeks
ended
28 September
2024
(Unaudited)
|
26 weeks
ended
23
September 2023
(Unaudited)
|
53 weeks
ended
30 March
2024
(Audited)
|
|
|
£ million
|
£
million
|
£
million
|
Interest expense on lease
liabilities
|
-
|
0.1
|
0.1
|
Other net interest
|
1.9
|
1.8
|
4.1
|
Interest payable
|
|
1.9
|
1.9
|
4.2
|
Net interest expense/(income) on
liabilities/return on assets on pension
|
|
0.6
|
(0.3)
|
(0.4)
|
Net finance costs
|
|
2.5
|
1.6
|
3.8
|
Notes to the condensed consolidated financial
statements
6
Taxation
|
|
26 weeks
ended
28 September
2024
(Unaudited)
|
26 weeks
ended
23
September 2023
(Unaudited)
|
53 weeks
ended
30 March
2024
(Audited)
|
|
|
£ million
|
£
million
|
£
million
|
Current tax - Overseas tax
and UK corporation tax
|
|
0.0
|
0.3
|
1.5
|
Deferred tax - UK tax charge
for temporary differences
|
-
|
-
|
(1.9)
|
Total tax charge/(credit)
|
|
0.0
|
0.3
|
(0.4)
|
In addition to the amount charged
to the income statement, deferred tax charge relating to retirement
benefit obligations amounting to £1.0 million has been charged
directly to other comprehensive income (H1 FY24: £3.1 million
credit).
7 (Loss)/earnings per
share
|
|
26 weeks
ended
28 September
2024
(Unaudited)
|
26 weeks
ended
23
September 2023
(Unaudited)
|
53 weeks
ended
30
March 2024
(Audited)
|
|
|
million
|
million
|
million
|
Weighted average number of shares in issue for the purpose of
basic earnings per share
|
|
563.8
|
563.8
|
563.8
|
Dilutive potential ordinary shares
|
|
-
|
6.9
|
7.7
|
Weighted average number of shares
in issue for the purpose of diluted earnings per share
|
|
563.8
|
570.7
|
571.5
|
|
|
|
|
|
|
|
|
|
|
|
|
£ million
|
£
million
|
£
million
|
(Loss)/profit for basic and diluted earnings per
share
|
|
(1.8)
|
1.7
|
3.3
|
Adjusted items
|
|
(0.4)
|
0.2
|
(0.2)
|
Tax effect of adjusted
items
|
|
-
|
-
|
-
|
Adjusted (loss)/earnings
|
|
(1.4)
|
1.5
|
3.5
|
|
|
|
|
|
|
|
|
|
|
|
|
£ million
|
£
million
|
£
million
|
|
|
|
|
|
|
|
|
|
|
|
|
Pence
|
Pence
|
Pence
|
Basic (loss)/earnings per
share
|
|
(0.3)
|
0.3
|
0.6
|
Basic adjusted
(loss)/ earnings per share
|
|
(0.3)
|
0.3
|
0.6
|
Diluted (loss)/earnings per
share
|
|
(0.3)
|
0.3
|
0.6
|
Diluted adjusted (loss)/earnings per share
|
|
(0.3)
|
0.3
|
0.6
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
The total dividend for the period
is nil pence per share (H1 FY24: nil pence per share).
Where there is a loss per share,
the calculation has been based on the weighted average number of
shares in issue, as the loss renders all potentially dilutive
shares anti-dilutive
Notes to the condensed consolidated financial
statements
8 Tangible fixed assets and Software
assets
There were no additions to
Right-of-use assets in the period.
Capital additions of £0.8 million
were made during the period (H1 FY24: £1.1 million). These
comprised tangible fixed assets of £Nil (H1 FY24: £0.1 million) and
software assets of £0.8 million (H1 FY24: £1.0 million).
9 Borrowings
The carrying value of the Group's
outstanding borrowings at 23 September 2023 was £19.9 million
(30 March 2024: £19.7 million)‌‌. The Group is required to achieve
certain royalty targets under its covenants. At 28 September 2024
the loan was repayable on demand due to breaches in certain loan
covenants. The loan has been refinanced after the period end,
refer to note 15 for further details.
The credit facility of
£19.9 million (30 March 2024:
£19.7 million) is secured on the
shares of specified obligor subsidiaries and the assets of the
Group not already pledged. The Group also holds a financial asset
of £0.5 million (30 March 2024:
£0.7 million) reflecting the expected
proceeds from the wind-down of the UK operations by the
administrators of Mothercare UK Ltd and Mothercare Business
Services Limited.
10 Retirement benefit
schemes
The Group has calculated the value
of its pension liability under IAS 19 as at 28 September 2024. The
FY24 year end assumptions have been rolled forward and updated
for changes in market rates over the current interim
period.
For the two schemes, based on the
actuarial assumptions from the actuarial valuations carried out as
of March 2024 and using the rolled forward assumptions referred to
above, a net obligation of £20.6 million (H1 FY24: £6.0
million) has been recognised. The increase in the liability
position was mainly due to returns on the assets being lower than
expected resulting in an asset experience loss.
11 Financial instruments: fair value
disclosures
The Group held the following
financial instruments at fair value at 28 September
2024.
|
|
Fair value measurements at 28
September 2024
(Unaudited)
|
Fair
value measurements at 23 September 2023
(Unaudited)
|
Fair
value measurements at 30 March 2024
(Audited)
|
|
|
£ million
|
£
million
|
£
million
|
|
|
|
|
|
Current financial assets:
|
|
|
|
|
Derivative financial instruments:
|
|
|
|
|
Financial asset
|
|
0.5
|
0.5
|
0.7
|
|
|
0.5
|
0.5
|
0.7
|
Notes to the condensed consolidated financial
statements
11 Financial
instruments: fair value disclosures (continued)
The Group's financial asset (Level 3
within the IFRS 7 hierarchy) represents a right, arising under the
sales purchase agreement with the administrators of MUK, to receive
the proceeds of the wind-up of the UK retail store estate and
website operations as repayment for the Group's secured borrowings.
It has been estimated by the administrators that the Group will
receive £0.5 million (H1 FY24: £0.5 million). Many of the outflows
which would impact the valuation of this financial asset are
finalised, with the final repayment being dependent on the amounts
to be received back by the merchant acquirer and final settlement
of VAT.
The Directors consider that the
carrying value amounts of financial assets and financial
liabilities recorded at amortised cost in the financial statements
are approximately equal to their fair values.
12 Share-based
payments
A charge is recognised for
share-based payments based on the fair value of the awards at the
date of grant, the estimated number of shares that will vest and
the vesting period of each award. The total net charge for
share-based payments under IFRS 2 is £0.1 million (H1 FY24: £0.1
million).
13 Notes to the
cash flow statement
|
26 weeks
ended
28 September
2024
(Unaudited)
|
26 weeks
ended
23
September 2023
(Unaudited)
|
53 weeks
ended
30 March
2024
(Audited)
|
|
£ million
|
£
million
|
£
million
|
(Loss)/profit from operations
|
0.7
|
3.6
|
6.7
|
Adjustments for:
|
|
|
|
Depreciation of property, plant and equipment and right of use
assets
|
0.1
|
0.1
|
0.1
|
Amortisation of intangible
assets
|
0.5
|
0.1
|
0.3
|
(Loss)/gain on non-cash foreign
currency adjustments
|
(0.1)
|
(0.1)
|
0.2
|
Share-based payments
|
0.1
|
0.1
|
0.2
|
Movement in provisions
|
(0.2)
|
(0.5)
|
(0.8)
|
Net gain
on financial derivative instruments
|
-
|
-
|
(0.2)
|
Payments
to retirement benefit schemes
|
(1.1)
|
(2.4)
|
(2.4)
|
Charge in
respect of retirement benefit schemes
|
0.7
|
0.7
|
1.7
|
Operating cash flow before movement in working
capital
|
0.7
|
1.6
|
5.8
|
Decrease
in inventories
|
0.3
|
0.7
|
0.3
|
(Increase)/decrease in receivables
|
(1.9)
|
1.5
|
2.4
|
(Increase)/decrease in payables
|
1.0
|
(3.7)
|
(2.5)
|
Cash generated from operations
|
0.1
|
0.1
|
6.0
|
Income taxes paid
|
(0.1)
|
(0.4)
|
(1.2)
|
Net
cash flow from operating
activities
|
-
|
(0.3)
|
4.8
|
|
Analysis of net debt
|
30 March
2024
|
Cash flow
|
Foreign
exchange
|
Non-cash
movements
|
28
September
2024
|
|
£
million
|
£
million
|
£
million
|
£
million
|
£ million
|
Cash and cash
equivalents
|
5.0
|
(2.3)
|
-
|
0.1
|
2.8
|
IFRS 16 lease
liabilities
|
(0.2)
|
0.2
|
-
|
-
|
-
|
Term loan
|
(19.7)
|
-
|
-
|
(0.2)
|
(19.9)
|
Net debt
|
(14.9)
|
(2.1)
|
-
|
(0.1)
|
(17.1)
|
|
|
|
|
|
|
Notes to the condensed consolidated financial
statements
14 Related party
transactions
Transactions between the Group and
its subsidiaries, which are related parties, have been eliminated
on consolidation and are not disclosed in this note. There was no
revenue earned from related parties in the current or prior
year.
15 Events after the
balance sheet date
The IP rights for the Mothercare
brand for India, Bhutan, Bangladesh, Sri Lanka and Nepal were
transferred to JVCO 2024 Ltd, which was a wholly owned subsidiary
of the Group, at a value of £33.3 million. On 17 October, in return
for a 51% equity interest in JVCO 2024, together with some royalty
concessions, the Group received a gross consideration of £16.0
million, from Reliance, our current franchise partner in
India.
From these proceeds Mothercare
repaid £11.5 million of its existing loan facility, reducing the
principal liability to £8 million and at the same time revised the
terms of facility including reducing the annual interest percentage
and revising the financial covenants. As part of the revision of
the loan facility, our lender, Gordon Brothers were granted new
warrants to subscribe up to 43.4m new ordinary shares of Mothercare
at a subscription price of 8.5p per share (the "Warrants"). These
Warrants, which are exercisable for 5 years from the date of issue,
contain certain anti-dilution rights which will operate so as to
secure for Gordon Brothers the right to subscribe for an aggregate
equity interest representing approximately 7% of the Company's
issued share capital (following exercise in full of the
Warrants).
Additional Disclosures
Risk management framework
A risk management framework is in
place which is appropriate for the size and complexity of the
business with consideration to its AIM listing, future partner and
system developments and Brand promotion and
evolution.
MGB maintains its risk management
function in line with the Quoted Companies Alliance Corporate
Governance Code (QCA Code) complying with AIM Rule 26. The Audit
& Risk Committee provides oversight, as to the overall
suitability and effectiveness of the risk management approach and
is accountable and supported by the Board. The Operating Board
formally reviews, discusses and documents the Principal Risks to
the business at least annually. The Risk Committee, which is
chaired by the CFO, sits quarterly to understand existing and
developing issues, and MGB Senior Managers contribute to and update
Operational Risk registers, as a minimum also quarterly. All
colleagues recognise their responsibility to proactively identify
and manage risk and opportunity in their daily activities and
planning.
Principal risks and uncertainties
Reviewed, discussed and agreed by
the Operating Board annually, MGB Principal Risks are designed to
promote strategic success and improve future performance, the
impact of operational risks on these determines the focus for
senior management and their teams. The following risks have been
agreed:
· Liquidity
· Dependency on a small number of partners
· Pension scheme funding
· Global
economic and political conditions
· ERP
system
· Regulatory and legal
· Brand,
reputation and relationships
· Personnel and talent
Directors' Responsibility statement
The Directors are responsible for
preparing the Interim Results for the 26-week period ended 28
September 2024 in accordance with applicable law, regulations and
accounting standards. The Directors confirm that to the best of
their knowledge the condensed consolidated interim financial
statements have been prepared in accordance with IAS 34: 'Interim
Financial Reporting', and that the interim management report
includes a fair review of the information required by DTR 4.2.7R
and DTR 4.2.8R, namely:
·
an indication of the important
events that have occurred during the first 26 weeks of the
financial year and their impact on the condensed consolidated
interim financial statements, and a description of the principal
risks and uncertainties for the remaining 26 weeks of the financial
year; and
· material related party transactions in the first 26 weeks of
the year and any material changes in the related party transactions
described in the last annual report.
The Directors of Mothercare plc
are listed on page 50 of the Mothercare plc Annual Report and
Financial Statements 2024. A list of directors is maintained on the
Mothercare plc website at: www.mothercareplc.com. With the
exception of today's announcement, there have been no changes since
the publication of the Annual Report.
By order of the Board
Clive Whiley
Andrew Cook
Chairman
Chief Financial Officer
2 December 2024